Neuroblastoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Irinotecan, Temozolomide, Dinutuximab Variant #01 Partial | — | R 3 932 | 21d | — | — | — | — | — |
Cyclophosphamide and Vincristine Variant #01 | — | R 384 | 14d | — | — | — | — | — |
Cyclophosphamide monotherapy N/A - secondary systemic drug | — | R 60 | 28d | — | ~15.8 mo | — | — | 1 |
Naxitamab monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
4 of 4 regimens shown